CURRICULUM VITAE

Name: Charles H. Evans, Jr., M.D., Ph.DPlace of Birth: Orange, New JerseyEducation:

1958 Graduated from Columbia High School, Maplewood, New Jersey1962 B.S., (Biology), Union College, Schenectady, New York1969 M.D., University of Virginia, Charlottesville, Virginia1969 Ph.D., (Microbiology-Immunology), University of Virginia Thesis: Fluorescein Isothiocyanate Probing of Human Immunoglobulin G Honors: Alpha Omega Alpha (National Medical Scholastic Honor Society)

Sigma Xi (National Scientific Honor Society)Raven Society (University of Virginia Scholastic Honor Society)Whitehead Fellow in Anatomy, 1964-1965Medical Scientist, Life Insurance Medical Research Fund, 1967-1969

Postgraduate Training:Intern in Pediatrics, University of Virginia Medical Center, Charlottesville, Virginia, 1969-1970.Resident in Pediatrics, University of Virginia Medical Center, Charlottesville, Virginia, 1970-1971. Research Associate, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 1971-1974.

Major Specialty Training:Pediatrics, Immunology & Microbiology, Oncology (Carcinogenesis), Medical Biotechnology, Health Science and Services Research, Administration & Governance

Professional Licensure, Certification, and Continuing Education:License to Practice Medicine and Surgery in the Commonwealth of Virginia, 1969-present.Diplomat, National Board of Medical Examiners, 1970.Fellow, American Academy of Medical Administrators, 1993; Credentialed health services administrator, 1996.

Professional Experience:

2002-presentProfessor , School of Nursing and Health Studies, Georgetown University,Washington, D.C. Health Studies Science Track Coordinator 2002-2003;Chair, Department of Human Science, 2003-present.

1998-2002 Executive Staff, Institute of Medicine, The National Academies (Science,Engineering and Medicine), Washington, D.C. Scholar-in-Residence, 2001-2002. Sr. Adviser, Biomedical and Clinical Research, 1999-2001. Head, Health Sciences Section, 1998-1999. . Analytical studies of

CV CH Evans

research needs and national policy in setting biomedical research priorities, patient protection institutional review board accreditation and

Professional Experience: (continued) function, equity distribution of organ donation and allocation for transplantation recipients, chemical and biological terrorism preparedness, disparities in cancer research and care, environmental justice, biomedical research ethics, strategies for small number participant clinical research trials, and a vision for space medicine during travel beyond Earth orbit.

1976-1998Chief of the Tumor Biology Section, National Cancer Institute.

Planned, executed and administered an investigator initiated basic science biomedical research program in the etiology and inhibition of cancer. As a principal investigator -

recruited, trained and supervised research students and postdoctoral fellows.

initiated national and international scientific research collaborations provided expertise in evaluation of national and international

research authored/co-authored >100 research publications discovered the cytokine leukoregulin see committee and advisory board service below for details of

career progression

1974-1976Research Scientist, National Cancer Institute, National Institutes of Health,Bethesda, Maryland.

Service in the Uniformed Services of the United States:

Medical Officer United States Public Health Service Commissioned Corps. Active duty 1971-1998. Retired, March 1998. Current rank: Captain, USPHS-ret.

Service on Scientific and Community Committees and Advisory Boards:

Georgetown UniversityMiddle States Periodic Review Steering Committee, 2006-present.Executive Faculty Committee on Intellectual Life, 2006-2007.Fellowships Endorsement Committee, 2004-present.Provost’s Undergraduate Learning Initiative, 2003-2008.Board of Directors, Center for New Discoveries in Learning and Scholarship

(CNDLS) 2003-2007.Provost’s Center for Science Advisory Committee, 2002-2003.Center for Clinical and Translational Science at Georgetown University MedStar Research Institute/Medstar Health and Virginia Tech Planning Committee, 2006-2008.Committee on Medical Education, Georgetown University Medical School, 2005-present.

2

CV CH Evans

School of Nursing & Health Studies Research Council, 2002-present.School of Nursing and Health Studies Committee on Students, 2002- present.

Other ProfessionalNational Aeronautics and Space Administration (NASA) Critical Care Medicine Working Group, 2000-2005. Space Surgeon Requirements Working Group, 2002-2005.American Academy of Medical Administrators, Continuing Certification

Credentialing Standards Committee, 2003-2006.National Dental Research Centers Study Section, National Institute of

Craniofacial Disorders and Dental Research, 1998-1999.Tumor Biology and Clinical Studies Section, Breast Cancer Research

Program, State of California, Office of the President, University of California, 1995.Special Emphasis Review Panel, National Institute of Dental Research, Regional Research Centers for Minority Oral Health Phase II, 1995.Tumor Biology and Therapy Study Section, Tobacco-Related Disease Research Program, State of California, Office of the President, University of California, 1993-1994.

Associate Editor, Journal of Cellular Biochemistry, 1989-present. Board of Trustees, Suburban Hospital Healthcare System, Bethesda,

Maryland. Advisory Council, 1987-1988; Trustee, 1988-1997. Trustee Emeritus 1997-present. Chairman, Governance Committee, 1989-1992. CEO Search Committee, 1992. Executive Personnel Committee, 1989-

1997. Hospital Medical Ethics Committee, 1993-1997. Chairman, MedicalAffairs Committee, 1994-1997.

Editorial Board, Journal of the National Cancer Institute, 1981-1993.Editorial Board, THE EXECUTIVE, journal of the American Academy of Medical Administrators, 1989-1992.

National Cancer Institute Laboratory Specialist Promotion Panel, 980-1985; Chairman, 1983-1985. Control of Chemical and Biological Hazards in the Laboratory, Division of Safety, NIH; Course Instructor, 1980-1983. National Cancer Institute Director's Immunology Working Group, 1977-1980. Carcinogenesis Collaborative Program Management Group, National Cancer Institute, 1977-1978.

Civic and CommunityBoard of Directors, Meadowkirk Meeting, Camp and Retreat Ministry, National Capital Presbytery, Washington, DC, Chairman 2008-

Board of Directors, The First Tee Montgomery, 2002-2005 Arts and Sciences College Board of Trustees (formerly Alumni Council), University of Virginia, 1987-1997. Vice-President 1993-1997; Publications

Committee Chairman, 1988-1993. Emeritus Trustee, 1998-present. Rotary Club of Bethesda-Chevy Chase, 1981-present; President, 1986-

1987. Board of Directors, Bethesda-Chevy Chase Rotary Club Foundation,

Inc., 1983-present; President, 1987-1988, 1997-1998.

3

CV CH Evans

Trustee and Ruling Elder, Bradley Hills Presbyterian Church, Bethesda, Maryland, 1975-78, 1986-1989, 1997-2002, 2006-present. Chair, Worship & Arts Lay Ministry 2006-present, Education & Nurture Lay

Ministry, 1997-2002. Board of Directors, Bradley Hills Presbyterian Church Nursery School, Bethesda, Maryland, 1978-1995; Chairman,

1987-1995. Civic and Community Service (continued): Board of Governors, Azalea Society of America, 1983-1989. National Convention Chairman, 1983, 1988. Editor-in-Chief, The Azalean, Journal of the Azalea Society of America, 1983-1988. Distinguished Service Award, 1989. President, Brookside Gardens Chapter, 2002- present.

Washington Committee of the Pro Musicis Foundation, 1986-1989. Boy Scouts of America, National Capital Area Council Exploring Committee, Health and Safety Chairman, 1990-1992

Professional Awards and Honors:

Innovative Teaching Award, Georgetown University School of Nursing and Health Studies, 2004.Fellow, American Association for the Advancement of Science, 1998.United States Public Health Service Outstanding Service Medal for research leadership in defining immune defenses against cancer, 1996.United States Public Health Service Unit Commendation for service interviewing

applicants to the Uniformed Services University of the Health Sciences, 1992.Sir Henry Wellcome Medal and Prize, 1990.

United States Public Health Service Commendation Medal for discovery of the immunologic hormone (cytokine) leukoregulin, 1985. John Horsley Memorial Prize for investigation in the fundamental medical

sciences, University of Virginia, 1982. United States Public Health Service Citation for "sustained high performance in achievement of scientific investigations and program objectives," 1980. Sigma Xi, Associate Member 1967, Full Member 1974. Alpha Omega Alpha, 1964.

Funded Research: (32 years of continuous support as a principal investigator) Evans, C., (2005-present). P.I., Pathways to Success; Goldman Sachs Foundation,

$260,000. Evans, C., (2002-2005). P.I., Community Building to Promote Biomedical Health Careers; National Center Research Resources, National Institutes of Health,

$300,000. Evans, C. (1999-2001). P.I., Creating a Vision for Space Medicine during Travel Beyond Earth Orbit; U.S. National Aeronautics and Space Administration, $1,400,000.

Evans, C. (1999-2000). P.I., Strategies for Small Number Participant Clinical Research Trials; U.S. National Aeronautics and Space Administration, $250,000.

Evans, C. (1999). P.I., National Town Meeting on Research Misconduct; U.S. Department of Health and Human Services, $50,000.

Evans, C. (1974-1998). P.I., Immunobiology of Carcinogenesis; National Cancer Institute, $5,000,00 over 25 years.

4

CV CH Evans

Inventions reduced to patent and practice:

Leukoregulin, an anti-tumor lymphokine and its therapeutic uses. U.S. patent 4,849,506. Leukoregulin Anti-viral therapy. U.S. patent 5,368,853. Leukoregulin Anti-Herpes Treatment. U.S. patent 5,529,771.

5

CV CH Evans

Membership (active) in Professional and Scientific Organizations:

Academy of Medicine of the District of ColumbiaAmerican Academy of Medical Administrators, Elected a Fellow, November 1993. Credentialed Fellow in Medical Administration, 1996.American Association for the Advancement of Science, Elected a Fellow, 1998.American Association for Cancer ResearchAmerican Association of ImmunologistsAmerican Society for Cell BiologyClinical Immunology Society (Charter Member).Cosmos Club, Washington, D.C.

Current Research and Scholarship

P.I. on study of effective means to build interest of talented rural American high school youth in pursuing biomedical science as a career. 2002—present.

Co-P.I. with Michael V. Relf, Ph.D., Chair of the Department of Professional Nursing at Georgetown University in determining the incidence of HIV-1 gene resistance to antiretroviral therapy in treatment naïve (untreated) individuals in the metropolitan Washington , D.C., region. 2005-present.

Faculty adviser and founder, annual Georgetown University UndergraduateStudent Research Conference, 2002-present.

Faculty adviser and founder, on-line undergraduate Georgetown University Journal of Health Science, 2002-present.

Development of undergraduate digital senior health science theses in collaboration with the Electronic Thesis and Dissertation Initiative of Digital Georgetown at Georgetown University. 2005-present.

Current Teaching and Presentation Activities:

Courses designed and taught (all undergraduate at Georgetown University).Language of Health and Disease, 3 credit hours, Spring 2003, 2004

Physiological Adaptation to Space Flight and other Extreme Environments, 3 credit hours, Fall and Spring 2003, 2004, 2005, 2006Epidemiologic Applications to Population Health, 3 credit hours, Spring 2004Health Promotion Disease Prevention Experiential Laboratory, 1 credit hour, Spring 2003, 2004, 2005, 2006Communicating Science Seminar, 1 credit hour, Fall and Spring 2002,2003

2004, 2005, 2006Contemporary Issues in Science Seminar, Fall and Spring 2004, 2005, 2006

Recent National PresentationsCommunity Building to Promote Careers in Biomedical Science. CH Evans, MI Klopf and AE French, AAAS National Meeting, February 2005 and American Society for Cell Biology Eucation Initiative Forum, December 2005.

Human Simulation in Discovering Limits of Human Physiological Adaptation.

6

CV CH Evans

CH Evans and RC Perez, AAAS National Meeting, February 2005.Organizer/Chairperson of National/International Scientific Meetings:

Organizer, Future Directions for Research with Small Number Participant Populations, National Academy of Sciences, September 2000.Organizer, Medicine in Extreme Environments, National Academy of Sciences, July 2000.Organizer, National Town Meeting to discuss the proposed New Common Federal Definition of Research Misconduct, National Academy of Sciences, September 1999.Co-organizer, XIX International Congress of Virology workshop: Cytokines, Interferons and Virokines in Virus Diseases, Glasgow, Scotland, August 6-13, 1993.

Co-organizer, 1992 Keystone Symposium: Cytokines in Growth, Development and Pathogenesis, Taos, New Mexico, February 1-8, 1992.Organizer, Biomolecular Recognition and Targeting Strategies in the Prevention And Treatment of Disease, University of Virginia, October 23-25, 1991.Co-organizer, VIII International Congress of Virology Workshop: Lymphokines and other Mediators in Virus Infections, Berlin, August 26-31, 1990.Co-organizer, 1990 American Society of Microbiology Symposium: Cytokines and Drugs: Biotherapies for Infectious Diseases, Anaheim, California, May 14, 1990.Co-organizer, 1990 UCLA Symposium: Molecular Pathways of Cytokine Action, Park City, Utah, January 27-February 3, 1990.Co-organizer 1988 UCLA Symposium: Mechanisms of Action and Therapeutic Application of Biologicals in Cancer and Immunodeficiency Diseases, Keystone,

Colorado, April 23-30, 1988.Organizer, 1987 UCLA Community Resource Coordination Workshop: Biotechnology Products for Treatment of Cancer and Immunodeficiency Diseases, Keystone, Colorado, April 3-4, 1987.l 23-30, 1988.Co-organizer, 1987 UCLA Colloquium: Biotechnology Products in Cancer, Therapy, Lake Tahoe, California, March 1-4, 1987.

Major Invited Biomedical National and International Lectures:

Plenary speaker, American Society of Cell Biology annual meeting, San Francisco, CA, December 13, 2005, “Community Building to Promote Careers In Biomedical Science”Keynote speaker, Medicine in 21st Century Symposium, New Jersey Medical School, Newark, NJ, June 4, 1997. “History of cytokines.”Plenary Speaker, Burroughs Wellcome Research Foundation Symposium on Innovations in Therapy of Human Viral Diseases, Research Triangle Park, NC, December 6-9, 1992. "Cytokine molecular target interactions and the design of antiviral biotherapeutics."Plenary Speaker, Keystone Symposium on Cytokines in Growth, Differentiation and Pathogenesis of Disease, Taos, NM, February 1-8, 1992. "Cytokines as Anti-viral Agents."Plenary Speaker, Biomolecular Recognition and Targeting Strategies in Prevention and Treatment of Disease, University of Virginia, Charlottesville, VA, October 22-25, 1991. "Cytokine modulation of target cell plasma membrane sensitivity to lymphocyte destruction."

7

CV CH Evans

8

CV CH Evans

Major Invited Biomedical National and International Lectures: (continued)

Plenary Speaker, 1990 American Society of Microbiology Symposium on Cytokine and Drugs: Biotherapies for Infectious Diseases, Anaheim, CA, May 14, 1990. "Leukoregulin: Potential therapeutic agent for infections & malignancies."Plenary Speaker, UCLA Symposium on Molecular Pathways of Cytokine Action, Park City, Utah, January 27-February 3, 1990. "Lymphokine enhancement of drug uptake."Speaker, 1989 American Cancer Society Science Writers Seminar, Irvine, California, April 2-5, 1989. "Leukoregulin enhancement of anti-cancer pharmacologic action- A new approach to drug delivery."Plenary Speaker, UCLA Symposium on Mechanism of Action and Therapeutic Application of Biologicals in Cancer and Immunodeficiency Diseases, Keystone, CO, April 1988. "Biological and molecular characteristics of leukoregulin action."Speaker, Second National Conference on Immunity against Cancer, Williamsburg, Virginia, November 9-11, 1987. "Leukoregulin."Plenary Speaker, UCLA Symposium on Membrane-Mediated Cytotoxicity, Park City, UT, March 1986. "Leukoregulin, lymphotoxin, and interferon transmembrane signaling and regulation of cell growth"Speaker, Workshop on Lymphotoxin, Tumor Necrosis Factor, and T, NK and Macrophage Cytotoxic Factors sponsored by the Cancer Research Institute at Memorial Sloan-Kettering Cancer Center, NY, December 1984, "Cell source, biological activities and specificity of lymphotoxin. "Plenary Speaker, 10th Anniversary of Flow Cytometry in Immunology, National Institutes of Health, Bethesda, MD. April 4, l984. "Identification of leukoregulin as an intrinsic mediator of natural killer cytotoxicity."Lecturer, Hauptseminar Biochemie, Biochemische Institute, Albert-Ludwigs Universitat, Freiburg im. Briesgau, Germany, July 1983. "Biochemica l properties and hormonal action of lymphotoxin."Lecturer in Experimental Oncology, Medicinische klinik A, University of Dusseldorf, Dusseldorf, Germany, June 1983. "Lymphokines, homeostasis, and carcinogenesis."Speaker, George Washington University 1983 Spring Symposium, "Thymic Hormones and Lymphokines," National Academy of Sciences, Washington, DC, June 1983. "The anti-cancer action of lymphotoxin."Consultant and speaker, Health Careers Conference on "Contemporary Perspectives in Biomedical Careers," Johnson C. Smith University, Charlotte, NC, March 1982.Medical Grand Rounds speaker and Visiting Professor of Medicine, University of Wisconsin, Madison, WI, June 1981. "Lymphotoxin - an immunologic hormone with anticarcinogenic and antitumor activity."Speaker, 1980-1981 Comprehensive Cancer Center Seminar Program, Pennsylvania State University Medical Center, Hershey, PA, November 1980. "The regulation of cell transformation by chemical and physical carcinogens."1980 Century Forum Lecturer and Visiting Professor of Medicine, University of Vermont, College of Medicine, Burlington, VT, November 1980. "Cancer and immunity: prevention of carcinogenesis by the normal immune system."

9

CV CH Evans

Major Invited Biomedical National and International Lectures: (continued)

Speaker, International Workshop on Short-Term Tests for Chemical Carcinogens, University of British Columbia, Vancouver, Canada, August,

1979. "In vitro mammalian cell transformation for identification of carcinogens,cocarcinogens and anticarcinogens."

Speaker, Advances in Cancer Biology I: In Vitro Carcinogenesis, Given Institute of Pathobiology, Aspen, Colorado, July, 1976. "Neoplastic transformation by chemicals of guinea pig fetal cells in culture."Speaker, Third Collaborative Conference, Carcinogenesis Program, Division of Cancer Cause and Prevention, National Cancer Institute, Orlando, Florida, February, 1975. "Colony inhibition mediated by nonimmune leukocytes in vitro and skin reactivity in vivo as indices of tumorigenicity in guinea pig cultures transformed by chemical carcinogens."Speaker, XI International Cancer Congress, Florence, Italy, October, 1974. "Properties of cells from different species accompanying chemical carcinogen induced transition to the neoplastic state."Speaker, Twenty-fourth Annual Meeting of the Tissue Culture Association, Boston, Massachusetts, June, 1973. "Chemical carcinogen induced neoplastic transformation in vitro."Speaker, Conference on Carcinogenesis Testing in the Development of New Drugs National Academy of Sciences, Washington, D.C., May, 1972. Chemical carcinogenesis of mammalian cells in culture: applicability to the evaluation of new drugs."

Publications in print and on-line:

120 articles, books, audio-visuals. 20 book chapters. 123 abstracts.

Abstracts are not included in the listing below

1. Boyd, A.C., Herzberg, E.M., Marshall, M.M., Lamparello, N.A., DeLeon, M.A., Porter, A., Evans, C.H. Jr., Doshi, S, Shahkolahi, A, Dekker, D, Relf, M: Antiretroviral drug resistance among treatment-naïve HIV-1 infected persons in Washington, DC. AIDS Patient Care and STDS 22: 445-448, 2008.

2. Evans, C.H. Saving the Creation. Sermon preached on August 26, 2007. http://www.bradleyhillschurch.org/article98488.htm

3. Lehnes, K. Winder, A.D., Alfonso, C., Kasid, N., Simmoneaux, M., Summe, H., Morgan, E., Iann, M.C., Duncan, J., Eagan, M., Tavaluc, R., Evans, C.H. Jr., Russell, R., Wang, A., Hu, F., Stoica, A.: The Effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase.Akt1 pathway. Endocrinology 148:1171-1180, 2007.

4. Cesari, W.A., Caruso, D.M., Zyka, E.L., Schroff, S.T., Evans, C.H. Jr., Hyatt, J.K.: Study of physiological responses to acute carbon monoxide exposure with

10

CV CH Evans

a human patient simulator. Adv. Physiol. Educ. 30: 242-247, 2006.

5. Evans, C.H. Spirituality and science converging in thin places. Sermon preached on August 13, 2006. http://www.bradleyhillschurch.org/article51865.htm 2006.

6. Evans ,C.H., Klopf, M.I., French A.L.: Community Building to Promote Careers in Biomedical Science. American Society of Cell Biology, Education Initiative Forums. http://www.ascb.org/newsfiles/charles_evans.swf 2006.

7. Klopf, N., McNeil, S., Evans, C.:  The Biomedical Institute Program. Documentary digital video at http://lumen.georgetown.edu/faculty/che3/, Georgetown University, 2005.

8. McSwain, N.E., Bogomolov, A.L., Cantrill, V.V., Chapman, S.V., Comtois, G., Damann, J., Davies, V., Doerr, H., Evans, C., Fisher, C., Gray, G., Gloss, D., Jacobs, L.M., Jones, J.A., Kuklinski, P., Legome, E., Lowery, D.W., Marx, J.A., Mercer, S., Morgun, V.V., Nicogossian, A.E., Pool, S.L., Pons, P. , Putcha,,L., Sawin, C.F., Sekiguchi, C., Tintinalli, J., Van Meter, K., White, R., Williams, D.R., Williams, R. Resuscitation and Critical Care in Space. NASA Technical Report Series, Johnson Space Center, Houston, Texas, February 2003, 94 pp.

9. Ball, J.R., Evans, C.H. Jr. (Eds.): Safe Passage: Astronaut Care for Exploration Missions. Washington, D.C., National Academy Press, 2001. [United States Library of Congress holding call number RC1135.I576 2001].

10. Evans, C.H. Jr., Ildstad, S.T. (Eds.): Small Clinical Trials: Issues and Challenges. Washington, D.C., National Academy Press, 2001. [United States Library of Congress holding call number R853.C55 S58 2001].

11. Gaiotti D., Chung,J., Iglesias M., Nees M., Baker P.D., Evans C.H., Woodworth C.D.: Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV- immortalized keratinocytes by a ras-dependent pathway. Mol. Carcinogenesis 27:97-109, 2000.

12. Young D.A., Evans, C.H., Smith, T.J.: Leukoregulin induction of protein expression in human orbital fibroblasts: Evidence for anatomical site-restricted cytokine-target cell interactions. Proc. U.S. Natl. Acad. Sci. 95:8904-8909, 1998.

13. Evans, C.H.: Cytokines and chemokines: Molecular keys to growth and differentiation. The Chemist 74:10-16, 1997.

14. Evans, C.H.: How to reduce the risk of severe infection in asplenic patients. Consultant 37:1166-1167, 1997.

15. Evans, C.H.: Virus cytokine interactions. In: Bertino, J.R., ed. Encyclopedia of

11

CV CH Evans

Cancer. Academic Press, Inc. New York, 1997, pp. 1995-2002.

16. Wang, H., Cao, H.J., Winn, V.D., Rezanka, L.J., Frobert, Y., Evans, C.H., Sciaky, D., Young, D.A., Smith, T.J.: Leukoregulin induction of prostaglandin endoperoxide H synthase-2 in human orbital fibroblasts: an in vitro model for connective tissue inflammation. J. Biol. Chem. 271:22718-22728, 1996.

17. Evans, C.H: Cytokines and viral anti-immune genes. Stem Cells 14:177-184, 1996.

18. Evans, C.H.: Cytokine and related host defense virus interactions. Drug News and Perspectives. 8:469-474, 1995.

19. Evans, C.H., Lee, T.S., Flugelman, A.A.: Spermine directed immunosuppression of cervical carcinoma cell sensitivity to a majority of lymphokine activated killer (LAK) lymphocyte cytotoxicity. Natural Immunity 14:157-163, 1995.

20. Hogg, M.G., Evans, C.H., Smith, T.J.: Leukoregulin induces plasminogen activator type-1 in human orbital fibroblasts. Am. J. Physiol. 269:359-366, 1995.

21. Zimonjic, D.B., Rezanka, L.J., Evans, C.H., Polymeropoulos, M., Trent, J.M., Popescu, N.C.: Mapping of the immune interferon gamma gene (IFNG) to chromosome band 12q14 by fluorescence in situ hybridization. Cytogenet and Cell Genet. 71:247-248, 1995.

22. Smith, T.J., Wang, H., Evans, C.H.: Leukoregulin is a potent inducer of hyaluronan synthesis in cultured orbital fibroblasts. Am. J. Physiol. 268:C382-388, 1995.

23. DiPaolo, J.A., Woodworth, C.D., Evans, C.H.: Cytokines inhibit human papillomavirus transcription and enhance cell sensitivity to lymphocyte killing. In: Monsonego, J., ed. Papillomavirus in Human Pathology. Rome: Serono Symposia Publications, pp449-457, 1995.

24. Mauviel, A., Lapière, Halcin, C., Evans, C.H., Uitto, J.: Differential Cytokine Regulation of Type I and Type VII Collagen Gene Expression in Cultured Human Dermal Fibroblasts. J. Biol. Chem., 269:25-28, 1994.

25. Evans, C.H.: Cytokines: Molecular keys to homeostasis, development and pathophysiology . J. Cell. Biochem. 54:1-3, 1993.

26. Mauviel, A., Chgen, Y., Dong, W., Evans, C.H., Uitto, J.: Transcriptional interactions of transforming growth-factor- with pro-inflammatory cytokines. Current Biol., 3:822-831, 1993.

27. Evans, C.H., Flugelman, A.A., DiPaolo, J.A.: Cytokine modulation of immune

12

CV CH Evans

defenses in cervical cancer. Oncol. 50:245-251, 1993.

28. Mauviel, A., Kähäri, V., Chen, Y.Q., Kurkinen, M., Evans, C.H., Uitto, J.: Transcriptional activation of fibroblast stromelysin-1 and collagenase gene expression by a novel lymphokine, leukoregulin. Trans. Assn. Amer. Phys. 105:100-109, 1992.

29. Evans, C.H., Baker, P.D.: Decreased expression of P-glycoprotein in multidrug sensitive and resistant human myeloma cells induced by the cytokine leukoregulin. Cancer Res. 52:5893-5899, 1992.

30. Mauviel, A., Kähäri, V., Kurkinen, M., Evans, C.H., Uitto, J.: Leukoregulin, a T-cell derived cytokine, up-regulates stromelysin-1 gene expression in human dermal fibroblasts. J. Cell. Biochem. 50:53-61, 1992.

31. Mauviel, A., Reitamo, S., Remitz, A., Lapière,J., Ceska, M., Baggiolini, M., Walz, A., Evans, C.H., Uitto, J.: Leukoregulin, a T-cell derived cytokine, induces interleukin-8 gene expression and secretion in human skin fibroblasts. J. Immunol. 149:2969-2976, 1992.

32. Mauviel, A., Evans, C.H., Uitto, J.: Leukoregulin down-regulates type I collagen mRNA levels and promoter activity in human dermal fibroblasts, and counteracts the up-regulation elicited by transforming growth factor-. Biochem. J. 284:629-632, 1992.

33. Mauviel, A., Kähäri, V., Evans, C.H., Uitto, J.: Transcriptional activation of fibroblast collagenase gene expression by a novel lymphokine, leukoregulin. J. Biol. Chem. 267:5644-5648, 1992.

34. Woodworth, C.D., Lichti, U., Simpson, S., Evans, C.H., DiPaolo J.A.: Leukoregulin and interferon gamma inhibit human papillomavirus (HPV) type 16 gene transcription in HPV-immortalized human cervical cells. Cancer Res. 52:456-463, 1992.

35. Fishelson, Z., Shlanger, S., Bomstein, Y., Evans, C.H.: The human lymphokine leukoregulin induces cell resistance to complement-mediated lysis. Immunol. Lett. 32:35-42, 1992.

36. Evans, C.H., Furbert-Harris, P.M., Flugelman, A.A., Woodworth, C.D., DiPaolo, J.A.: Synergistic regulation of LAK lymphocyte cytotoxicity by combination cytokine and cisplatin treatment. Combination Therapies. A.L. Goldstein and E. Garaci (Eds.), Plenum Press, New York, 1992, pp. 237-244.

37. Yan, B., Baker, P.D., Evans, C.H., Marsh, J.W.: Influence of endogenous thy1.1 cells upon the efficacy of an anti-thy1.1 antibody-diphtheria toxin conjugate. Bioconjug. Chem. 2:207-210, 1991.

13

CV CH Evans

38. Hooks, J.J., Detrick, B., Evans, C.H.: Leukoregulin, a novel cytokine enhances the anti-herpesvirus actions of acyclovir. Clin. Immunol. Immunopath. 60:244-253, 1991.

39. Mauviel, A., Rédini, F., Hartmann, D.J., Pujol, J., Evans, C.H.: Modulation of human dermal fibroblast extracellular matrix metabolism by the lymphokine leukoregulin. J. Cell Biol. 113:1455-1462, 1991.

40. Detrick, B., Evans, C.H., Chader, G.J., Hooks, J.J.: Cytokine-induced modulation of cellular proteins in retinoblastoma. Analysis by flow cytometry. Investig. Opthalmol. & Visual Sci. 32:1714-1722, 1991.

41. Evans, C.H., Hooks, J.J., Detrick, B.: Leukoregulin: a new biotherapeutic cytokine in the search for more effective anti-viral pharmacologic agents. Mil. Med. 156: 155-159, 1991.

42. Evans, C.H.: Growth and differentiation - fulfilling the dream. J. Cell Biochem. 45: 1-2, 1991.

43. Evans, C.H., Baker, P.D.: Leukoregulin enhancement of tumor inhibitory drug uptake. In: Cytokines in Hemopoiesis, Oncology and Aids, Eds. M. Freund, H. Link, and K. Welte. Springer Verlag, Berlin, 1990, pp. 331-336.

44. DiPaolo, J.A., Woodworth, C.D., Furbert-Harris, P.M., Evans, C.H.: Immunomodulation of HPV16 immortalized exocervical epithelial cells. In Gross, E., Jabolonska, S., Pfister, H., and Stegner, H-E. (Eds.): Genital Papillomavirus Infections: Advances in Modern Diagnosis and Therapy. Springer, Berlin-Heidelberg-New York, 1990, pp. 283-299.

45. Slingluff, C.L. Jr., Seigler, H.F., Darrow, T.L., Evans, C.H.: Implications of leukoregulin to autologous tumor specific human T-cell populations. J. Biol. Resp. Modifers 9:387-394, 1990.

46. Evans, C.H., Furbert-Harris, P.M., Woodworth, C.D., DiPaolo, J.A.: Lymphokine modulation of HPV16 transfected cervical epithelial cell sensitivity to natural killer lymphocyte cytotoxicity. In: Papillomaviruses. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 124, Eds. P. Howley and T. Broker. Alan R. Liss, Inc., New York, 1990, pp. 145-155.

47. Evans, C.H.: Commitment to Quality - The Pledge to total quality management at DHHS. Executive, 28: (2):3, 1990.

48. Hooks, J.J, Chader, G., Evans, C.H., Detrick, B.: Interferon-gamma enhances the expression of retinal S-antigen, a specific neuronal cell marker. J. Neuroimmunol., 26:245-250, 1990.

14

CV CH Evans

49. Barnett, S.C., Evans, C.H.: Influence of extracellular calcium on cell permeablization and growth regulation by the lymphokine leukoregulin. J. Cell. Biochem., 43:89-101, 1990.

50. Evans, C.H., Barnett, S.C., Gelleri, B.A., Furbert-Harris, P., Sheehy, P.A., Barker, J.L., Baker, P.A., Wilson, A.C., Farley, E.K., D'Alessandro, F.: Biological and molecular characteristics of leukoregulin action. In Groopman, J.E., Evans, C.H. and Golde, D.W. (Eds.): Mechanisms of Action and Therapeutic Applications of Biologicals in Cancer and Immune Deficiency Disorders. New York, N.Y., Alan R. Liss, Inc., 1989, pp. 315-329.

51. Groopman, J.E., Golde, D.W., Evans, C.H. (Eds.): Mechanisms of Action and Therapeutic Applications of Biologicals in Cancer and Immune Deficiency Disorders. New York, N.Y,, Alan R. Liss, Inc., 1989. [United States Library of Congress holding call number RC271.B53 M43 1989].

52. Furbert-Harris, P., Evans, C.H.: Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity. Cancer Immunol. Immunother., 30:86-91, 1989.

53. Furbert-Harris, P.M., Evans, C.H., Woodworth, C.D., DiPaolo, J.A.: Loss of leukoregulin up-regulation of NK but not LAK lymphocytotoxicity in human papilloma virus 16 DNA-immortalized cervical epithelial cells. J. Natl. Cancer Inst., 81:1080-1085, 1989.

54. Evans, C.H., Wilson, A.C., Gelleri, B.A.: Preparative isoelectric focusing in ampholine electrofocusing columns versus immobiline polyacrylamide gel for the purification of biologically active leukoregulin. Anal. Biochem. 177:358-363, 1989.

55. Evans, C.H.: Leukoregulin. Prog. Clin. Biol. Res., 288:259-270, 1988.

56. Barnett, S.C., Evans, C.H.: Leukoregulin induced translocation of protein kinase C activity in K562 cells. Clin. Exptl. Immunol., 73:505-509, 1988.

57. Evans, C.H., Baker, P.D.: Tumor-inhibitory antibiotic uptake facilitated by leukoregulin: A new approach to drug delivery. J. Natl. Cancer Inst., 80:861-864, 1988.

58. Sheehy, P.A., Barnett, S.C., Evans, C.H., Barker, J.L.: Activation of ion channels in tumor cells by leukoregulin, a cytostatic lymphokine. J. Natl. Cancer Inst., 80:868-871, 1988.

59. Evans, C.H., DiPaolo, J.A.: Chemico-biological interactions in the immunologic modulation of initiated and promoted transformation. In Elmore, E.L.,

15

CV CH Evans

Langenbach, R.J. and Barrett, J.C. (Eds.): Tumor Promoters: Biological Approaches for Mechanistic Studies and Assays., New York, N.Y., Raven Press, 1988, pp. 179-186.

60. Evans, C.H.: Mechanisms of leukoregulin anti-cancer action. In Ransom, J.H. and Ortaldo, J. (Eds.): Leukolysins and Cancer: Biological and Chemical Aspects, Clifton, N.J., The Humana Press, Inc., 1988, pp. 198-216.

61. Borden, E.C., Bradley, E.C., Evans, C.H., Fox, C.F., Metzgar, R.S., Mitchell, M.S., Weinstein, J.N.: Biotechnology products in cancer therapy: A colloquium. Cancer Res., 48:223-225, 1988.

62. Evans, C.H., Heinbaugh, J.A., Ransom, J.H.: Flow cytometric evaluation of leukoregulin as an intrinsic molecular mediator of natural killer lymphocyte cytotoxicity. Lymphokine Res., 6:277-297, 1987.

63. Evans, C.H., Barnett, S.C.: Comparative chromatography of lectins and bioactivity recovery of the immunologic hormone leukoregulin on derivatized silica and on cross-linked agarose molecular sizing HPLC matrices. J. Chromatogr., 390:391-400, 1987.

64. vans, C.H.: ASA’s 1986 Garden State party. The Azalean, 8:561-52, 1986.

65. Evans, C.H., Barnett, S.C.: Leukoregulin transmembrane signals and regulation of cell growth. In Bonavida, B., Collier, J.R. (Eds).: Membrane Mediated Cytotoxicity, UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 45. New York, Alan R. Liss, Inc., 1986, pp. 423-437.

66. Barnett, S.C., Evans, C.H.: Leukoregulin increased plasma membrane permeability and associated ionic fluxes. Cancer Res., 46:2686-2692, 1986.

67. Das, K.K., Basu, M., Basu, S., Evans, C.H.: Biosynthesis in vitro of GalNAc ß1-3-containing globoside and Forssman glycolipid by two N-acetylgalactosaminyl-transferases from chemically transformed guinea pig cells. Carbohydrate Res., 149:119-135, 1986.

68. Evans, C.H.: Come alive in ‘85- A Mobile chronicle. The Azalean, 7:49-51, 1985.

69. Evans, C.H.: 1985 Guide to azalea hardiness. The Azalean, 7:78-83, 1985.

70. Evans, C.H. and Miller W. C. III: Pattern of sporting. The Azalean, 7:1-2, 1985.

71. Ransom, J.H., Evans, C.H., McCabe, R.P., Hanna, M.G., Jr.: The mechanism of leukoregulin enhancement of target cell susceptibility to NK cell mediated cytotoxicity in humans. In Henkart, P. (Ed.): Mechanisms in Cell Mediated Cytotoxicity II. New York, Plenum Publ. Co., 1985, pp. 281-287.

16

CV CH Evans

72. Barnett, S.C., Evans, C.H.: Membrane permeability changes induced by the anti-tumor lymphokine leukoregulin. In Hellman, K. and Eccles, S.A. (Eds.): Treatment of Metastasis, Problems and Prospects. London, Taylor and Frances, 1985, pp. 295-298.

73. DiPaolo, J.A., Doniger, J., Evans, C.H., and Popescu, N.C.: Enhancement and inhibition of transformation of Syrian hamster embryo cells. Carcinog. Compr. Surv., 8:319-328, 1985.

74. Ransom, J.H., Evans, C.H., McCabe, R.P., Pomato, N., Heinbaugh, J.A., Chin, M., Hanna, M. G., Jr.: Leukoregulin, a direct-acting anti-cancer immunologic hormone that is distinct from lymphotoxin and interferon. Cancer Res., 45:851-862, 1985.

75. Evans, C.H.: Origins of the evergreen hybrids Ben Morrison and B. Y. Morrison. The Azalean, 6:11-12, 1984.

76. DiPaolo, J.A., Doniger, J., Popescu, N.C., Evans, C.H.: Modulation of radiation induced transformation by combinations of a phorbol diester and a lymphotoxin. Toxicologic Path., 12:168-172, 1984.

77. McCabe, R.P., Oneson, R., Evans, C.H.: Mechanism of natural delayed-type hypersensitivity reactions to tumor cells in nonimmunized syngeneic guinea pigs. Cancer Immunol. Immunother., 17:76-82, 1984.

78. Sukamar, S., Pulciani, S., Doniger, J., DiPaolo, J.A., Evans, C.H., Zbar, B., Barbacid, M.: A transforming ras gene in tumorigenic guinea pig cell lines initiated by diverse chemical carcinogens. Science, 223:1197-1199, 1984.

79. McCabe, R.P., Evans, C.H.: Secretion of proteinase inhibitors by tumorigenic and non-tumorigenic guinea pig and Syrian hamster fibroblasts: evidence for autocrine regulation of local proteolysis. Cancer Res., 44:1392-1397, 1984.

80. DiPaolo, J.A., Evans, C.H., DeMarinis, A.J., Doniger, J.: Inhibition of radiation-initiated and -promoted transformation of Syrian hamster embryo cells by lymphotoxin. Cancer Res., 44:1465-1471, 1984.

81. Evans, C.H., Ransom, J.H.: The anti-cancer action of lymphotoxin. In Goldstein, A. L. (Ed.): Thymic Hormones and Lymphokines. New York, Plenum Publ. Co., 1984, pp. 357-364.

82. Evans, C.H.: Normal levels of lymphotoxin secretion by freshly isolated and refrigerated human peripheral blood lymphocytes. J. Immunol. Meth., 67:13-20, 1984.

17

CV CH Evans

83. Evans, C. H.: Azalea potting and growing mixes: Recipes from growers coast to coast. The Azalean, 5:60-64, 1983.

84. Ransom, J.H., Evans, C.H.: Molecular and biological characterization of anticarcinogenic and tumor cell growth-inhibitory activities of Syrian hamster lymphotoxin. Cancer Res., 43:5222-5227, 1983.

85. Ransom, J.H., Pintus, C., Evans, C.H.: Lymphotoxin amplification of tumor growth inhibition is specific for natural killer cells not macrophages. Int. J. Cancer, 02:93-97, 1983.

86. Ransom, J.H., Evans, C.H., Jones, A.E., Zoon, R.A., DiPaolo, J.A.: Control of the carcinogenic potential of 99mtechnetium by the immunologic hormone lymphotoxin. Cancer Immunol. Immunother., 15:126-130, 1983.

87. Evans, C.H.: Lymphokines, homeostasis, and carcinogenesis. J. Natl. Cancer Inst., 71:253-258, 1983.

88. McCabe, R.P., Evans, C.H., DiPaolo, J.A.: Relationship of neoantigens induced by 3-methylcholanthrene treatment of Syrian hamster embryo cells to antigens expressed on fetal and 3-methylcholanthrene transformed neoplastic cells. Oncodevelop. Biol., 4:383-393, 1983.

89. Pintus, C., Ransom, J.H., Evans, C.H.: Endothelial cell growth supplement: A cell cloning factor that promotes the growth of monoclonal antibody producing hybridoma cells. J. Immunol. Meth., 61:195-200, 1983.

90. Fuhrer, J.P., Evans, C.H.: The anticarcinogenic and tumor growth inhibitory activities of lymphotoxin are associated with altered membrane glycoprotein synthesis. Cancer Lett., 19:283-292, 1983.

91. McCabe, R.P., Evans, C.H.: The regulatory role of extracellular proteases in tumor growth. Surv. Synth. Path. Res., 2:1-9, 1983.

92. Evans, C.H., Heinbaugh, J.A., DiPaolo, J.A.: Comparative effectiveness of lymphotoxin anticarcinogenic and tumor cell growth inhibitory activities. Cell. Immunol., 76:295-303, 1983.

93. Fuhrer, J.P., Evans, C.H., Ransom, J.H., Heinbaugh, J.A.: Identification of lymphotoxin as the predominant molecular class of in vitro and in vivo Syrian hamster lymphotoxin. Cell. Immunol., 75:63-70, 1983.

94. Greiner, J.W., Evans, C.H., DiPaolo, J.A.: Carcinogen-induced phenotypic alterations in mammary epithelial cells accompanying the development of neoplastic transformation. Cancer Res., 43:273-278, 1983.

18

CV CH Evans

95. Basu, S., Basu, M., Higashi, H., Evans, C.H.: Biosynthesis and characterization of globoside and Forrsman glycosphingolipids in guinea pig tumor cells. In: A. Makita, S. Handa, T. Taketomi and Y. Nagai, (Eds.): New Vistas in Glycolipid Research. New York, Plenum Publishing Corp., 1982, pp. 131-137.

96. DiPaolo, J.A., Evans, C.H., DeMarinis, A.J., Doniger, J.: Phytohemagglutinin inhibits phorbol diester promotion of UV irradiation initiated transformation in Syrian hamster embryo cells. Int. J. Cancer, 30:781-786, 1982.

97. DiPaolo, J.A., Evans, C.H., Milo, G.E.: The susceptibility of normal hamster and human cells to transformation by environmental agents. In Armstrong, B., and Bartsch, H. (Eds.): Host Factors in Human Carcinogenesis, Lyon, IARC Scientific Publications, pp. 561-569, 1982.

98. Evans, C.H., DiPaolo, J.A.: Independent expression of chemical carcinogen-induced phenotypic properties frequently associated with the neoplastic state in a cultured guinea pig cell line. J. Natl. Cancer Inst., 69:1175-1182, 1982.

99. Fuhrer, J.P., Evans, C.H.: Rapid separation of biologically active Syrian hamster lymphotoxin in high yield by size exclusion high performance liquid chromatography. J. Chromatog., 248:427-433, 1982.

100. Greiner, J.W., Evans, C.H.: Temporal dynamics of cortisol and dexamethasone prevention of benzo(a)pyrene-induced morphological transformation of Syrian hamster cells. Cancer Res., 42:4014-4017, 1982.

101. Ransom, J.H., Evans, C.H., DiPaolo, J.A.: Lymphotoxin prevention of diethylnitrosamine carcinogenesis in vivo. J. Natl. Cancer Inst., 69:741-744, 1982.

102. Evans, C.H., DiPaolo, J.A., Heinbaugh, J.A., DeMarinis, A.J.: Immunomodulation of the lymphoresponsive phases of carcinogenesis by natural immunity. J. Natl. Cancer Inst., 69:737-741, 1982.

103. Ransom, J.H., Evans, C.H.: Lymphotoxin enhances the susceptibility of neoplastic and preneoplastic cells to natural killer cell mediated destruction. Int. J. Cancer, 29:451-458, 1982.

104. Evans, C.H., Boynton, A.L.: Calcium dependence of chemical carcinogen induced morphological transformation of Syrian hamster embryo cells. Cancer Lett., 15:271-279, 1982.

105. Evans, C.H.: Lymphotoxin--an immunologic hormone with anticarcinogen and antitumor activity. Cancer Immunol. Immunother., 12:181-190, 1982.

19

CV CH Evans

106. Ransom, J.H., Rundell, J.O., Heinbaugh, J.A., Evans, C.H.: Biological and physicochemical characterization of keyhole limpet hemocyanin-induced guinea pig lymphotoxin. Cell. Immunol., 67:1-13, 1982.

107. McCabe, R.P., Evans, C.H.: Relationship of plasminogen activator, fibronectin production, sensitivity to lymphotoxin cytotoxicity, and natural delayed-type skin reactivity to tumorigenicity of chemical carcinogen transformed guinea pig cells. J. Natl. Cancer Inst., 68:329-336, 1982.

108. Evans, C.H., DiPaolo, J.A.: Equivalency of endothelial cell growth supplement to irradiated feeder cells in carcinogen induced morphological transformation of Syrian hamster embryo cells. J. Natl. Cancer Inst., 68:127-132, 1982.

109. DiPaolo, J.A., Evans, C.H., Popescu, N.C., Doniger, J.N.: Regulation of mammalian cell transformation. In Hecker, E. (Ed.): Cocarcinogenesis and Biological Effects of Tumor Promoters, Vol. 7, New York, Raven Press, 1982, pp. 273-276.

110. DiPaolo, J.A., DeMarinis, A.J., Evans, C.H., Doniger, J.: Expression of initiated and promoted stages of irradiation carcinogenesis in vitro. Cancer Lett., 14:243-249, 1982.

111. Evans, C.H., Heinbaugh, J.A.: Lymphotoxin cytotoxicity, a combination of cytolytic and cytostatic cellular responses. Immunopharmacology, 3:347-359, 1981.

112. Ohanian, S.O., McCabe, R.P., Evans, C.H.: Immunogenicity of guinea pig cells transformed in culture by chemical carcinogens. J. Natl. Cancer Inst., 67:1363-1368, 1981.

113. Shu, S., Steerenberg, P.A., Hunter, J.T., Evans, C.H., Rapp, H.J.: Adoptive immunity to the guinea pig line 10 hepatoma and the nature of in vitro lymphoid-tumor cell interactions. Cancer Res., 41:3499-3506, 1981.

114. Evans, C.H.: The role of lymphotoxin in natural cell-mediated cytotoxicity. Cell. Immunol., 63:1-15, 1981.

115. Greiner, J.W., Evans, C.H., DiPaolo, J.A.: Carcinogen-induced anchorage-independent growth and in vivo lethality of human MRC-5 cells. Carcinogenesis, 2:359-363, 1981.

116. Evans, C.H., DiPaolo, J.A.: In vitro mammalian cell transformation for identification of carcinogens, cocarcinogens, and anticarcinogens. In Stich, H. and San, R. H. C. (Eds.): Short-Term Tests for Chemical Carcinogens, Springer-Verlag, New York, 1981, pp. 306-322.

20

CV CH Evans

117. Evans, C.H., Greiner, J.W.: Corticosteroid prevention of carcinogenesis in benzo(a)pyrene or ultraviolet irradiation treated Syrian hamster cells in vitro. Cancer Lett., 12:23-27, 1981.

118. Evans, C.H., DiPaolo, J.A.: Lymphotoxin: an anticarcinogenic lymphokine as measured by inhibition of chemical carcinogen or ultra-violet irradiation induced transformation of Syrian hamster cells. Int. J. Cancer, 27:45-49, 1981.

119. Rundell, J.O., Evans, C.H.: Species specificity of guinea pig and human lymphotoxin colony inhibitory activity. Immunopharmacology, 3:9-18, 1981.

120. Sisskin, E.E., Weinstein, I.B., Evans, C.H., DiPaolo, J.A.: Plasminogen activator synthesis accompanying chemical carcinogen-induced in vitro transformation of Syrian hamster and guinea pig fetal cells. Int. J. Cancer, 26:331-336, 1980.

121. Rundell, J.O., Evans, C.H.: Biological characterization of guinea pig lymphotoxin production. Immunopharmacology, 2:19-27, 1979.

122. Evans, C.H.: Neoplastic transformation by chemicals of guinea pig fetal cells in culture. In Saffiotti, U., and Autrup, H. (Eds.): In Vitro Carcinogenesis. Guide to the Literature, Recent Advances and Laboratory Procedures. National Cancer Institute Carcinogenesis Technical Report Series No. 44 (1978), DHEW Pub. No. (NIH) 78-844, U.S. Gov't Printing Office, Washington, D. C., pp. 82-83.

123. Evans, C.H., Rabin, E.S., DiPaolo, J.A.: The susceptibility of guinea pig cells to the colony inhibitory activity of lymphotoxin during carcinogenesis. Cancer Res., 37:898-903, 1977.

124. Zbar, B., Ribi, E., Kelly, M., Granger, D., Evans, C.H., Rapp, H.J.: Immunologic approaches to the treatment of human cancer based on a guinea pig model. Cancer Immunol. Immunother., 1:127-138, 1976.

125. Basu, M., Basu, S., Shanabruch, W.G., Moskal, J.R., Evans, C.H.: Lectin and cholera toxin binding to guinea pig tumor (104C1) cell surfaces before and after glycospingolipid incorporation. Biochem. Biophys. Res. Commun., 71:385-392, 1976.

126. Popescu, N.C., Evans, C.H., DiPaolo, J.A.: Chromosome patterns (G and C bands) of in vitro chemical carcinogen-transformed guinea pig cells. Cancer Res., 36:1404-1413, 1976.

127. Evans, C.H., DiPaolo, J.A.: Comparison of nude mice with the host species for evaluation of the tumorigenicity of guinea pig and hamster cells transformed in vitro by chemical carcinogens. Cancer Res., 36:128-131, 1976.

21

CV CH Evans

128. Evans, C.H., DiPaolo, J.A.: Properties of cells from different mammalian species accompanying chemical carcinogen induced transition to the neoplastic state. Proc. XI Inter. Cancer Congress, Florence, 1974. Excerpta Medica International Congress Series, Amsterdam, 1975, pp. 118-121.

129. Hsiung, G.D., Fong, D.K.Y., Evans, C.H.: Prevalence of endogenous oncornavirus in guinea pigs. Intervirology, 3:319-331, 1975.

130. Zwilling, B.S., Meltzer, M.S., Evans, C.H.: Differential cytotoxicity of tumorigenic and nontumorigenic strain-2 guinea pig cells mediated by syngeneic phytohemagglutinin stimulated peritoneal exudate cells. J. Natl. Cancer Inst., 54:743-747, 1975.

131. Evans, C.H., Cooney, A.M., DiPaolo, J.A.: Colony inhibition mediated by nonimmune leukocytes in vitro and skin reactivity in vivo as indices of tumorigenicity of guinea pig cultures transformed by chemical carcinogens. Cancer Res., 35:1045-1052, 1975.

132. Evans, C.H., DiPaolo, J.A.: Neoplastic transformation of guinea pig fetal cells in culture induced by chemical carcinogens. Cancer Res., 35:1035-1044, 1975.

133. Evans, C.H., Ohanian, S.H., Cooney, A.M.: Tumor specific and Forssman antigens of guinea pig hepatoma cells: comparison of tumor cells grown in vivo and in vitro. Int. J. Cancer, 15:512-521, 1975.

134. Olinici, C.D., Evans, C.H., DiPaolo, J.A.: Chromosome patterns of nontransformed variants from chemical transformed Balb/3T3 cells. J. Cell. Physiol., 83:401-408, 1974.

135. Evans, C.H., DiPaolo, J.A.: Mammalian cells for carcinogen identification. J. Am. Med. Assoc., 225:631-632, 1973.

136. DiPaolo, J.A., Nelson, R.L., Donovan, P.J., Evans, C.H.: Host-mediated in vivo - in vitro assay for chemical carcinogenesis. Arch. Path., 95:380-385, 1973.

137. Atuk, N.O., Evans, C.H.: Hypertension as a localizing sign of mass lesions of brainstem. N. Eng. J. Med., 287:1355-1356, 1972.

138. Evans, C.H., Westfall, V., Atuk, N.O.: Astrocytoma mimicking the features of pheochromocytoma. N. Eng. J. Med., 286:1397-1399, 1972.

139. Evans, C.H.: Fluorescein isothiocyanate probing of human immunoglobulin G. Thesis, University of Virginia Library, 1969.

140. Evans, C.H., Herron, S.B., Goldstein, G.: Antibody activity associated with the

22

CV CH Evans

fuorescent polypeptide chains of human immunoglobulin G. J. Immunology, 101:915-923, 1968.

May 2008

23